Extremely low frequency electromagnetic fields prevent chemotherapy induced myelotoxicity

Electromagnetic Biology and Medicine

Volumn 26, Issue 4, 2007, Pages 277-281

  Rossi, Edoardo ^a   Corsetti, Maria Teresa ^a   Sukkar, Samir ^a   Poggi, Claudio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Studio Poggi ^*  (Italy)

Author keywords

Antioxidative treatment; Chemo radiotherapy; Hodgkin's lymphoma; Ion cyclotron resonance; Myelotoxicity

Indexed keywords

ELECTROMAGNETIC FIELDS; OXIDATIVE STRESS; PATIENT TREATMENT; TOXICITY; TUMORS;

ANTIOXIDATIVE TREATMENT; CHEMO-RADIOTHERAPY; HODGKIN'S LYMPHOMA; ION CYCLOTRON RESONANCE;

CHEMOTHERAPY;

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; ELECTROMAGNETIC FIELD; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMAGNETIC FIELDS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMOGLOBINS; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 37549065170     PISSN: 15368378     EISSN: 15368386     Source Type: Journal    
DOI: 10.1080/15368370701761984     Document Type: Conference Paper

References (13)

1. Aleman, B. M. P., van den Belt-Dusebout, A. W., Klokman, W. J., van't Veer, M. B., Bartelink, H., van Leeuwen, F. E. (2003). Long-term cause-specific mortality of patients treated for Hodgkin's disease. J. Clin. Oncology 21:3431-3439.
2. Conklin, K. A. (2000). Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr. Cancer 37:1-18.
3. Cornelli, U., Terranova, R., Luca, S., Cornelli, M., Alberti, A. (2001). Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J. Nutrition 131:3208-3211.
4. Kagan, V. E., Gleiss, B., Tyurina, Y. Y. et al. (2002). The role for oxidative stress in apoptosis: Oxidation and externalization of phosphatidylserine is required for macrophages clearance of cells undergoing Fas-mediated apoptosis. J. Immunol. 169:487-499.
5. Mantovani, G., Maceiò, A., Madeddu, C., Mura, L., Massa, E., Gramignano, G., Lusso, M. R., Murgia, V., Camboni, P., Ferreli, L. (2002). Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J. Cell. Mol. Med. 4:570-582.
6. Martingale, J. L. et al. (2002). Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 192:1-15.
7. Myers, C. (1998). The role of iron in Doxorubicyn-induced cardiomyopathy. Semin. Oncol. 25:10-14.
8. Pascale, C., Formengo, P., Epifani, G., Bosio, F., Giacometto, F. (2002). Cardioprotection of trimetazidine and anthracycline-induced acute cardiotoxic effects. Lancet 359:1153-1154.
9. Prasad, K. N. (2004). Multiple dietary antioxidants enhances the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integrative Cancer Ther. 3:310-322.
10. Raggi, F., Vallesi, G., Ruffini, F. et al. Medical care with "SEQEX®" apparatus balances the oxidative scale in healthy volunteers: a clinical investigation of medical device. {In press).
11. Savarese, D. M., Savy, G., Vahdat, L. et al. (2003). Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat. Rev. 29:501-513.
12. Shacter, E., Williams, J. A., Hinson, R. M., Senturker, S., Lee, Y. (2000). Oxidative stress interferes with cancer chemotherapy: inibition of lymphoma cell apoptosis and phagocytosis. Blood 96:307-313.
13. Sparano, J. A. (1998). Use of Dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Sem. Oncol. 25:66-71.